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Abstract
In Epstein-Barr virus infected epithelial cancers, the alternatively spliced BamHI A rightward
transcripts (BARTs) are abundantly expressed and are the template for two large clusters of
miRNAs. This study indicates that both of these clusters independently can inhibit apoptosis in
response to etoposide in an epithelial cell line. The Bcl-2 interacting mediator of cell death (Bim)
was identified using gene expression microarrays and bioinformatic analysis indicated multiple
potential binding sites for several BART miRNAs in the Bim 3’UTR Bim protein was reduced by
Cluster I and the individual expression of several miRNAs, while mRNA levels were unaffected.
In reporter assays, the Bim 3' untranslated region (UTR) was inhibited by both clusters but not by
any individual miRNAs. These results are consistent with the BART miRNAs downregulating
Bim post-transcriptionally in part through the 3’UTR and suggest that there are miRNA
recognition sites within other areas of the Bim mRNA.
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INTRODUCTION
Epstein-Barr Virus (EBV) is a member of the Herpes virus family that infects greater than
90% of the human population yet is associated with a number of malignancies (Rickinson
and Kieff, 2001). These cancers develop in both epithelial and lymphoid cells and include
Burkitt’s lymphoma (BL), Hodgkin’s disease, post-transplant lymphoma, nasopharyngeal
carcinoma (NPC), and gastric carcinoma (Fukayama, Hino, and Uozaki, 2008; Raab-Traub,
2002; Young and Murray, 2003). EBV expression within the tumors is predominantly latent
with expression of a small subset of the more than 100 genes potentially encoded by the
virus. There are at least three distinct forms of latent infection marked by different patterns
of viral gene expression. The viral genes expressed in the cancers are thought to contribute
to the induction of uncontrolled cellular growth and several of these proteins have
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transforming properties in vitro. Recently it has been discovered that EBV also encodes for
at least 25 microRNAs (miRNAs), many of which are highly expressed during latency (Cai
et al., 2006; Grundhoff, Sullivan, and Ganem, 2006; Pfeffer et al., 2004; Zhu et al., 2009). It
is likely that these miRNAs contribute to the growth changes induced during EBV latent
infections. Uncovering the function of these miRNAs may identify new mechanisms by
which EBV infection leads to transformation and malignancy.
miRNAs are approximately 22 nucleotide long noncoding RNAs that closely resemble small
interfering RNAs (siRNAs) in size and function. However, unlike siRNAs, miRNAs are
most often generated from RNA polymerase II transcripts in higher eukaryotes, which are
processed by the RNase III enzyme Drosha/DGCR8 complex to form approximately 60
nucleotide hairpin precursors known as pre-miRNAs (Bartel, 2004; Cullen, 2006). The pre-
miRNAs are exported to the cytoplasm via Exportin 5 where the mature form of the miRNA
is cleaved out of the hairpin by the RNase III enzyme Dicer (Bartel, 2004; Cullen, 2006).
The mature miRNA is then incorporated into a protein complex known as the RNA-induced
silencing complex (RISC) and targeted to the 3’UTR of an mRNA based on base pair
complementarity, most importantly with nucleotides 2–8 of the miRNA, which is known as
the seed sequence (Bartel, 2004; Cullen, 2006). The binding of the miRNA/RISC complex
to the 3’UTR of the target mRNA was originally thought to repress translation of the
targeted mRNA with partial complementarity to the target site or promote mRNA
degradation with complete complementarity (Bartel, 2004). Multiple studies indicate that
expression can be targeted in both ways. Transfection of miRNAs into cells identified
decreased levels of many mRNAs containing seed sequence matches to the particular
miRNAs (Lim et al., 2005). Additionally, a recent study comparing mRNA sequencing data
with proteomic data sets suggested that at least for several human miRNAs, changes in
mRNA levels and not changes in rates of translation, correlated to changes in protein levels
(Guo et al., 2010). However, in multiple instances in which specific miRNA targets have
been examined on an individual basis, regulation primarily occurs at the protein level
without a corresponding decrease in mRNA levels. Significantly, this mode of regulation
has been demonstrated for several viral miRNAs, such as miR-H2-3p and miR-H6 of
HSV-1, which are able to decrease viral expression exclusively at the protein level (Umbach
et al., 2008).
The EBV miRNAs are produced as two clusters from RNAs that are also differentially
expressed in the different latent expression patterns. Three miRNA precursors are encoded
near the BHRF1 gene and are apparently produced from an intron within the long EBNA
transcript (Cai et al., 2006). These miRNAs have only been detected in Type 3 latency that
is characteristic of transformed B-lymphocytes and post-transplant lymphoma. The
remaining 22 precursors are encoded in the introns of the Bam HI A region rightward
transcripts (BARTs) (Cai et al., 2006; Grundhoff, Sullivan, and Ganem, 2006; Pfeffer et al.,
2004; Zhu et al., 2009). The BART transcripts were originally identified in NPC (Gilligan et
al., 1990; Hitt et al., 1989) and are most abundant in Type 1 and Type 2 latency, the more
restricted patterns of EBV latent infection that are characteristic of the majority of the EBV
associated cancers (Rickinson and Kieff, 2001). Multiple studies have used quantitative RT-
PCR to examine the expression of EBV miRNAs in multiple cell lines, disease states, tumor
samples and during lytic reactivation (Amoroso et al., ; Cosmopoulos et al., 2009; Pratt et
al., 2009). These studies have largely supported the data generated from Northern blots and
direct cloning/sequencing methods with regard to the patterns of EBV miRNA expression
and have revealed heterogeneity in the relative abundance of individual miRNAs in different
cell lines or samples (Cai et al., 2006; Edwards, Marquitz, and Raab-Traub, 2008; Kim do et
al., 2007; Lung et al., 2009; Zhu et al., 2009).
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Potential functions have been identified for some of the EBV miRNAs. Several of the
miRNAs negatively regulate viral transcripts. miR-BART2 is encoded antisense to the
3’UTR of the viral DNA polymerase, BALF5, and thus has perfect complementarity to the
BALF5 transcript and can decrease the levels of mRNA and protein (Barth et al., 2008).
Both latent membrane protein 1 and 2 (LMP1 and 2) are decreased by BART miRNAs
through imperfect complementary sites in the 3’UTRs of their respective transcripts (Lo et
al., 2007; Lung et al., 2009). A few cellular targets have also been identified. miR-BHRF1-3
targets the T-cell attracting chemokine, CXCL-11 (Xia et al., 2008). miR-BART2 also
targets the stress induced molecule MICB (Nachmani et al., 2009). Additionally, miR-
BART5 has been shown to target p53 up-regulated modulator of apoptosis (PUMA), a
proapototic protein belonging to the BH3-only class of the Bcl-2 family, and inhibit
apoptosis (Choy et al., 2008).
In this study, the BART miRNAs coding region was cloned in two constructs and expressed
exogenously in the AGS gastric carcinoma cell line, a cell line that can be infected with
EBV resulting in altered growth properties (Kassis et al., 2002). In these cell lines, both
BART constructs inhibited apoptosis in response to etoposide treatment, suggesting that
multiple miRNAs regulate this process. Using a combination of microarray and
bioinformatic analysis, several potential targets of the BART miRNAs were identified that
could contribute to the protection from apoptosis. Of these potential targets, multiple
miRNA predicted binding sites were identified for the Bcl-2 interacting mediator of cell
death (Bim) and Bim protein was decreased in cell lines expressing several of the BART
miRNAs.
RESULTS
Generation of epithelial cell lines that express the EBV BART miRNAs
To determine the role of EBV BART miRNAs in promoting epithelial cell cancers, pcDNA3
constructs that express the two clusters of BART miRNAs with different selectable markers
were stably expressed in AGS cells, a human gastric carcinoma derived cell line (Barranco
et al., 1983). Four cell lines were created including a control with the two pcDNA3 vectors,
a cell line that contains both clusters, and two cell lines that express each cluster individually
in addition to the appropriate control vector (Figure 1). Expression of the miRNAs was
determined using Northern blotting and qRT-PCR in comparison with the C666-1 NPC cell
line (Cheung et al., 1999). This cell line expresses high levels of the BART miRNAs and has
been used as the reference level in most studies that have quantified the BART miRNAs.
Northern blotting identified expression of miR-BART4 from Cluster I and miR-BART9
from Cluster II (Figure 2A). miR-BART4 was expressed at levels slightly lower than in
C666-1 cells, however, miR-BART9 was expressed at slightly higher levels than C666-1
cells.
In order to confirm expression observed through Northern blotting and expand this data to
additional miRNAs, the Qiagen miScript system for qRT-PCR of miRNAs was used. To
validate the ability of this system to accurately measure relative abundance of EBV
miRNAs; C666-1 total cellular RNA, which contains abundant EBV miRNAs, was diluted
to varying degrees with AGS total cellular RNA, which does not contain EBV miRNAs.
PCR was then performed for nine different BART miRNAs using an equal amount of total
RNA input but with varying concentrations of C666-1 RNA (and thus varying
concentrations of BART miRNAs). Cycle thresholds (CTs) obtained were compared to
theoretical results based on the fraction of the input RNA that originated from C666-1 cells,
where the expected CT was equal to the CT obtained from undiluted C666-1 RNA plus log2
[total RNA]/[C666-1 RNA]. In the majority of cases, the qRT-PCR performed very well,
with CTs increasing at the expected rate as the amount of C666-1 RNA decreased (Figure
Marquitz et al. Page 3













2B). In a few instances the measured CTs were larger than the expected at some dilutions;
suggesting that with decreasing concentrations of miRNAs, this system for PCR may
underestimate the level of expression of some miRNAs. However, it should be possible to
use this system to determine the relative level of expression of BART miRNAs compared to
C666-1 cells with reasonable confidence. Evaluation of these nine individual miRNAs
representative of both clusters in the AGS stable cells confirmed expression of the multiple
miRNAs in each cell line and corroborated the Northern blot data, with miRNAs from
Cluster I expressed at levels slightly lower than C666-1 cells and miRNAs from Cluster II
expressed at the same to slightly higher levels than C666-1 cells (Figure 2C). Importantly,
these data indicated that the AGS stable cell lines express the EBV BART miRNAs at
physiologically relevant levels.
Both Clusters of BART miRNAs are capable of inhibiting apoptosis
In order to determine potential effects of the BART miRNAs in inhibiting apoptosis, the cell
lines expressing the BART miRNAs were treated with etoposide, an inhibitor of
topoisomerase II, that is known to induce apoptosis in a wide variety of cells (Montecucco
and Biamonti, 2007; van Maanen et al., 1988). Cells expressing both clusters of miRNAs
were treated with two concentrations of etoposide for 24 hours, and apoptosis was measured
by PARP cleavage (Figure 3A). Cells expressing the miRNAs had more uncleaved PARP at
both concentrations. To identify which cluster is responsible for this inhibition, apoptosis
was induced in all four AGS cell lines at both concentrations of etoposide (Figure 3B).
Strikingly, cells containing either cluster of miRNAs had more uncleaved PARP than
control cells at both concentrations. Determination of the percentage of cleaved PARP
relative to total PARP indicated that the individual clusters and in combination had
considerably less cleaved PARP compared to the total (Figure 3C). Analysis of the same
lysates for caspase-3 revealed decreased levels of the cleaved and activated form in cells
expressing either miRNA clusters (Figure 3B). These findings indicate that miRNAs in both
clusters can protect the AGS cells from apoptotic stimuli.
Microarray analysis of AGS cells expressing miRNAs
To determine how the BART miRNAs inhibit apoptosis it is essential to identify the cellular
transcripts that are targeted by specific miRNAs. Some miRNA targets have been
successfully identified through the use of expression microarrays (Lim et al., 2005).
However, this approach is difficult as many targeted mRNAs either do not decrease in
abundance or are only slightly decreased and are likely to not be detected by array. One
approach has been to use multiple mRNA microarray analyses to obtain statistical
significance and several miRNA targets have been successfully identified in this way
(Gottwein et al., 2007; Samols et al., 2007; Ziegelbauer, Sullivan, and Ganem, 2009).
Four replicate whole genome expression microarrays were performed on the cells expressing
both clusters of miRNAs. The effects on mRNA levels were small with no potential targets
having statistical significance of p<0.05 in a standard t-test. Of the genes with detectable
expression on the array, 944 genes had gene ontology annotations indicating involvement in
apoptosis. Of these, 133 genes were decreased in all four arrays compared to control cells
(Supplementary Table 1). Six of these genes; PUMA, Bim, Bik, BNIPL, HRK, and Bcl-G;
belonged to the BH3-only group of the Bcl2 family. The BH3-only proteins are pro-
apoptotic members of the larger Bcl2 family that control the release of cytochrome c from
the mitochondria and thus are central regulators of apoptosis (Lomonosova and Chinnadurai,
2008). The detection of PUMA using this approach was consistent with the previous
identification that PUMA was a target of miR-BART5 (Choy et al., 2008).
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To address whether any of these BH3-only genes are direct targets of the BART miRNAs,
the 3’UTR of each gene was analyzed for potential miRNA binding sites. Identification of
targets for viral miRNAs is difficult as many prediction algorithms rely on identification of
conservation between human and mouse genomes in predicted target sites in 3’UTRs as an
effective way to eliminate false positives. The rhesus lymphocryptovirus has conserved
miRNAs with EBV(Cai et al., 2006), however evolutionarily rhesus is so closely related to
human that the cellular UTRs are totally conserved and not useful to eliminate potential
targets. Due to this limitation, the PITA prediction program was chosen to identify potential
BART miRNA target sites in each 3’UTR. PITA uses the difference in free energy between
the binding of the miRNA to 3’UTR with the energy needed to disrupt the predicted
secondary structure of the 3’UTR in that location (Kertesz et al., 2007). Each BH3-only
gene had at least one predicted target site in the 3’UTR of the corresponding mRNA (Table
1). PITA also successfully predicted the miR-BART5 target site identified in the PUMA
3’UTR (Choy et al., 2008). Of the six BH3-only genes identified by the expression arrays,
Bim had the largest number and highest scoring target sites.
Bim is a target of multiple BART miRNAs
To identify effects on these potential targets from the microarray analysis, cell lysates of the
four AGS cell lines were analyzed by immunoblotting for protein expression of PUMA,
Bim, Bik, and BNIPL (Figure 4A). Expression of BNIPL could not be detected with
available antibodies (data not shown). The microarray analysis suggested that BNIPL is
expressed at an extremely low level, possibly explaining the lack of detection by Western
blotting. There are two isoforms of PUMA (α and β) detected by immunoblotting. Although
PUMA has been shown to be targeted by miR-BART5, PUMAα was downregulated in the
cell lines containing either cluster of miRNAs (Choy et al., 2008). PUMAβ was only slightly
decreased in cells expressing the first cluster of miRNAs, despite both isoforms sharing a
common 3'UTR (Figure 4A, B). Bik was predicted to be targeted by miR-BART11 in
Cluster II, however, the Bik protein level was not reduced by either cluster individually or in
combination (Figure 4A).
Importantly, expression of Bim was clearly decreased in the Cluster I cell line and was
further decreased in the cell line expressing both clusters. Bim can exist in three
alternatively spliced isoforms, BimEL, BimL, and BimS, however, only BimEL was detected
in AGS cells. The BimEL protein signal was reduced more than two fold in the cell lines that
express the Cluster I miRNAs (Figure 4A, B). There are several targets sites predicted in the
3’UTR of Bim for Cluster I miRNAs including miR-BART1-5p, 4, and 5, as well as
additional sites for Cluster II miRNAs miR-BART9, 11-3p, 11-5p, 12, and 18-3p (Table 1
and Figure 5A). These data suggest that the combined expression of the miRNAs in Cluster
I miRNAs is sufficient to downregulate Bim at the protein level and that the addition of
Cluster II miRNAs further decreases its expression.
MicroRNAs have been shown to disrupt protein translation and additionally may decrease
the mRNA levels of the target. Bim was identified due to the small mRNA decrease detected
by microarray, however, this potential effect on transcription was not detected using
quantitative RT-PCR to measure Bim mRNA (Figure 4C). Quantitative PCR was performed
with primers specific to the Bim coding sequence, and the dissociation curves revealed
specific peaks with the appropriate melting temperature after 20–25 cycles of PCR,
indicating this assay was faithfully measuring the levels of Bim mRNA. This finding
suggests that the downregulation of Bim occurs primarily post-transcriptionally and is
consistent with regulation by miRNAs.
To determine whether the BART miRNAs act via the Bim 3' UTR, reporter assays were
developed. The entire 4.2 kb Bim 3' UTR containing the 16 predicted BART miRNA
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binding sites was fused to a Renilla luciferase reporter in a single vector that also expresses
Firefly luciferase as a transfection control from a separate promoter (Figure 5A). The ratio
of expression was determined to identify specific effects on the Bim 3' UTR. The activity
regulated by the Bim 3'UTR was decreased by both clusters of miRNAs, suggesting that the
Cluster II miRNAs also negatively regulate the Bim 3' UTR (Figure 5B).
To further delineate functional sites in the 3' UTR, the two additional reporter constructs
were generated that contained either the first or the second half of the 3’UTR. Each of these
constructs contains numerous potential binding sites of the BART miRNAs (Figure 5A).
The 5' half contains 8 predicted sites for Cluster I miRNAs and 1 site for miR-BART12
while the 3' half contains sites for 5 miRNAs in Cluster II and 2 sites for miR-BART4 from
Cluster I. Surprisingly, Cluster I did not affect either construct while Cluster II slightly
decreased activity the 5' half of the UTR reporter (Figure 5B). These data further illustrate
the complexity of translational regulation by miRNAs and suggest that binding to the entire
UTR by one or multiple miRNAs is required for regulation in this cell line (Figure 5B). It is
possible that the complex regulation by multiple miRNAs in part reflects the length of the
Bim 3' UTR.
In order to further define the contribution of the individual BART miRNAs in the
downregulation of Bim, individual miRNAs were cloned into the pcDNA3 vector. These
vectors were designed similarly to the vectors expressing the entire clusters, with smaller
pieces of EBV genomic DNA being amplified and cloned into the expression vector.
However, in some cases miRNA expression was not detected when using DNA fragments
specific for a single miRNA. Cell lines expressing miR-BART1, 3, 5, and 9 were generated
and expression was confirmed by RT-PCR (Figure 6A). Expression of miR-BART4, 11 and
12 was not detected in the individual cell lines despite being expressed from similarly sized
fragments of DNA. However, it was possible to express these miRNAs by including the
adjacent miRNA in the expression vector, so cell lines that express miR-BART4 with miR-
BART3 or miR-BART1 and a cell line that expresses miR-BART11 and 12 together were
also generated (Figure 6A).
Analysis of the BimEL protein levels in cells expressing the miRNAs revealed that its
expression was affected by several of the individual miRNAs with cell lines expressing
miR-BART1, 3, 9, 11 and 12 all having decreased BimEL levels (Figure 6B and C). The cell
lines expressing miR-BART9 and miR-BART11 and 12 had the strongest and most
consistent downregulation of Bim, with some decrease detected in miR-BART1 and miR-
BART3 expressing cells. Surprisingly, expression of miR-BART1 and 3 together or in
combination with miR-BART4 did not appear to have an additive effect in decreasing Bim
expression. Notably miR-BART5, which has two predicted target sites in the Bim 3' UTR,
did not decrease Bim and Bim expression was consistently higher in the miR-BART5 cell
line than in the control. Additionally none of the individual miRNAs, including miR-
BART5, decreased the expression of PUMA (Figure 6B). Interestingly in the luciferase
reporter assay, the reporter activity of the Bim 3’UTR was not downregulated in any of the
individual expressing cell lines (Figure 6D). These findings confirm that multiple miRNAs
are required to negatively regulate the full length 3' UTR.
DISCUSSION
In this study, an effect on the inhibition of apoptosis was identified for the EBV BART
miRNAs and the data indicate that apoptosis may be targeted through effects on multiple
cellular genes. One important target was shown to be the BH3 only, Bcl2 family member
Bim, which is predicted to contain multiple miRNA binding sites in the 3’UTR of the Bim
message. Bim expression at the protein level was decreased in the Cluster I cell line and in
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several cell lines expressing individual miRNAs. Interestingly, both Cluster I or Cluster II
could decrease activity in the luciferase reporter assays but this repression required the entire
3’UTR. Additionally, none of the individual miRNAs could decrease reporter activity. This
may indicate that the miRNA target sites that are responsible for the decreased endogenous
protein level are within the 5' UTR or the coding region of the Bim mRNA and therefore
would not be detected by the reporter assay that solely measures the activity against the
3’UTR. Although the data suggest that the BART miRNAs decrease Bim protein, it is also
possible that the miRNAs act indirectly to decrease the levels of Bim through effects on
positive cellular regulators. However, considering that the clusters of miRNAs affect both
the endogenous Bim and a 3’UTR reporter, potential indirect effects might reflect effects on
cellular miRNAs that would target the 3'UTR to regulate Bim translation. Future studies on
the complex regulation of the Bim 3’UTR should clarify this point.
This study focuses on regulation of apoptosis in response to the chemical compound
etoposide. Etoposide is known to induce a p53 dependent cell death in a wide variety of cell
lines (Montecucco and Biamonti, 2007; van Maanen et al., 1988). Interestingly, EBV
malignancies often show a striking lack of p53 mutations (Edwards and Raab-Traub, 1994;
Effert et al., 1992), suggesting that EBV encodes for functions that can inhibit p53 mediated
apoptosis to promote carcinogenesis. This study has shown that the BART miRNAs can
serve to inhibit apoptosis that is induced through a p53 dependent mechanism. Of note, the
inhibition of apoptosis seen in this study was more apparent at 5μM etoposide than at
25μM. The degree to which PARP cleavage and caspase activation occurs in response to
etoposide was observed to be concentration dependent. At lower concentrations, and thus
less caspase activation, the BART miRNAs were more capable of inhibiting this process,
suggesting that the inhibition of apoptosis is incomplete. Perhaps in the context of a full
viral infection, other viral factors combine with the BART miRNAs in order to enact a more
efficient arrest of apoptosis.
Bim is now the second member of the BH3-only group of the Bcl2 family that has been
shown to be a target of the BART miRNAs, in addition to PUMA, and other members of
this family may also be targets for BART miRNAs (Choy et al., 2008). Four other family
members were also decreased as detected by the microarray analysis and each gene contains
potential miRNA target sites in the 3’UTR of their corresponding transcripts. However,
decreased Bik was not detected at the protein level and BNIPL is apparently expressed at
very low levels in AGS cells given its low intensity on the microarrays, and could not be
detected by Western blotting. BNIPL may be a target of the BART miRNAs in cells that
express this gene. The two other BH3 only group members were detected by microarray,
Hrk and Bcl-G (which exists as two alternatively spliced isoforms, one of which contains
only a BH3 domain), have yet to be evaluated. Other prominent members of the BH3 only
group of genes include Bad, Bid, and Noxa (Lomonosova and Chinnadurai, 2008).
However, effects on expression of Bad or Bid by the BART miRNAs were not detected in
the AGS cell line (data not shown).
It is likely that multiple differences between cell lines contribute to different effects of the
miRNAs. PUMA was not downregulated by miR-BART5 in the AGS cell lines generated in
this study when it was clearly shown to be targeted by Choy et al. Potentially different levels
of PUMA mRNA in the cell lines used in the two studies likely contribute to regulation by
miRNAs. Differences in cellular miRNA expression could also affect the activity of viral
miRNAs through their effects on the cellular transcript. Several cellular miRNAs have been
identified that regulate the 3’UTR of the Bim transcript. The miR-17-92 cluster of miRNAs,
which is highly expressed in several forms of cancer, contains two miRNAs that target Bim,
miR-19 and miR-92 (Ventura et al., 2008). miR-25, a member of the miR-106b-25 cluster,
also represses Bim in a gastric cancer cell line (Petrocca et al., 2008). Additionally, miR-221
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and miR-222 that are induced by activation of the ERK-MAPK pathway also decrease Bim
(Terasawa et al., 2009).
It has been previously shown that Bim is decreased during latent EBV infection of B
lymphocytes as infection of EBV negative Burkitt’s lymphoma cell lines with EBV leads to
posttranscriptional downregulation of Bim which is dependent upon the ERK-MAPK
pathway (Clybouw et al., 2005). The ERK-MAPK pathway is thought to downregulate Bim
through phosphorylation and subsequent ubiquitin mediated degradation (Ley et al., 2003;
Luciano et al., 2003; Mouhamad et al., 2004). EBV LMP1 activates the ERK signaling
pathway and thus could contribute to this decrease of Bim in lymphocytes (Liu et al., 2003;
Mainou, Everly, and Raab-Traub, 2007). Interestingly, in transformed lymphocytes where
the BART miRNAs are not expressed, the EBV latent proteins EBNA3A and EBNA3C also
decrease Bim transcription (Anderton et al., 2008) through an epigenetic mechanism
involving methylation of the Bim promoter (Paschos et al., 2009). Perhaps the BART
miRNAs replace some of the EBNA functions during different forms of latency. The fact
that the virus has evolved multiple mechanisms to inhibit Bim suggests that the prevention
of Bim mediated apoptosis is critical for the viral life cycle.
MATERIALS AND METHODS
Cell Culture and Constructs
The gastric carcinoma cell line AGS was grown in F-12 media (Gibco) with 10% fetal
bovine serum and antibiotic/antimycotic (Gibco). Stable cell lines expressing miRNAs were
generated by transfection of pcDNA3 constructs and selection in media containing 500 μg/
ml G418 (Gibco) and 400 μg/ml zeocin (Invitrogen) as required.
The pcDNA3 miRNA constructs were generated by PCR amplification of the miRNA
containing fragments from genomic EBV DNA followed by insertion into the BamHI/EcoRI
sites of pcDNA3.1 neo (Cluster I) or pcDNA3.1 zeo (Cluster II). The primers used for
Cluster I amplification were G1 (TTTGGATCCCGGAATATGCAAGTGCATCTT) and G2
(TTTGAATTCTAGAGGCTCTCCCAACACAAT), which generates a 1413 base pair
fragment containing the Cluster I miRNAs; and G9
(TATAGATCTATCCTTCTTCGGTAGGGAG) and G6
(TATGAATTCAAGGAAAGGCCTGCTGTCAT), which generates a 3185 base pair
fragment containing the Cluster II miRNAs. The Cluster II fragment does not contain miR-
BART21 which was identified subsequent to the beginning of this study (Zhu et al., 2009).
The individual miRNAs were cloned as fragments of approximately 250 base pairs in size,
and inserted into pcDNA3.1 zeo. The primers used for amplification were as follows:
5’BART1 (TTTAAGCTTCTACTTGCCTCGGCATCTC) and 3’BART1
(TTGGATCCGGTGGGGTCGTGACTATAT) for miR-BART1; 5’BART3
(TTTAAGCTTCTCCTTGTCTTGATAATCCCTG) and 3’BART3
(TTGGATCCCCCCCCCGTATAGATTT) for miR-BART3; 5’BART3 and 3’BART4
(TTGGATCCGTTTGTTAACCCCTTCTCCGG) for miR-BART3-4; 5’BART3 and
3’BART1 for miR-BART3-4-1; 5’BART4
(TTTAAGCTTGCCTCAGTGCCACTTTTACC) and 3’BART1 for miR-BART4-1;
5’BART5 (TTTAAGCTTTCTGTTAACCAGGTCAGTGG) and 3’BART5
(TTGGATCCGTTTATCAATTGTGGGATATGG) for miR-BART5; 5’BART9
(TTTAAGCTTTGGGTGGTGCTATGGGCTCC) and 3’BART9
(TTGGATCCCCTCACGTTGGCCAGGAAAGGG) for miR-BART9; and 5’BART11
(TTTAAGCTTACACCTTTGAGGACAC) and 3’BART12
(TTGGATCCTAACACATAAGCGCACAAGCGG) for miR-BART11-12.
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The Bim reporter constructs were made amplifying the Bim 3’UTR from human genomic
DNA and cloning into the XhoI/NotI sites in between the Renilla luciferase coding sequence
and the poly(A) site of psiCHECK-2 (Promega). The primers used for the amplification
were 5’BimFL (TTTTGTCGACCAGGTTCTTTGCGGAGCC) and 3’BimFL
(TTTTGCGGCCGCATTGCACAAGTAAAGTGGCAATTA). The two half UTR reporters
were generated by cutting the full length plasmid with XhoI (which cleaves at an internal
site in the UTR approximately in the middle) and NotI to generate a fragment that contains
the second half of the UTR. This fragment was recloned into an empty psiCHECK-2 vector
while the first half vector was generated by a blunt ligation of the remaining vector after the
second half was removed.
Western Blot analysis
Protein lysates were prepared from cells and Western blot analysis was performed as
previously described (Mainou, Everly, and Raab-Traub, 2005). Primary antibodies used
were rabbit α-PARP (Cell Signaling, 9542), rabbit α-Bim (Cell Signaling, 2819), rabbit α-
PUMA (Cell Signaling, 4976), rabbit α-Bik (Cell Signaling, 4592), rabbit α-Caspase-3
(Abcam, ab47131) and goat α-GRP78 (Santa Cruz, C-20). For etoposide treatment
experiments, cells were grown to 75% confluency, and then treated with indicated amount of
etoposide for 24 hours followed by harvesting the cells for Western blotting procedure.
Northern Blot analysis and quantitative RT-PCR
Total cellular RNA was prepared from cells using TRIzol reagent (Invitrogen) as was
previously described (Edwards, Marquitz, and Raab-Traub, 2008). Northern Blots for miR-
BART4 and miR-BART9 were performed as previously described (Edwards, Marquitz, and
Raab-Traub, 2008). Quantitative RT-PCR was performed for the BART miRNAs using the
miScript system (Qiagen) according to manufacturer’s instructions. Briefly, miRNAs are
polyadenylated and then reversed transcribed using an oligo-dT primer that contains a
universal tag at the 5’ end. A subsequent PCR step is then performed using a primer that
corresponds to the universal tag and a primer that is specific for each miRNA (primers are
specifically designed by Qiagen, the sequences of which are not made available to the
consumer). PCR product accumulation is monitored by the addition of SYBR green dye.
The cycle threshold (CT) was determined as the number of PCR cycles required for a given
reaction to reach an arbitrary fluorescence value within the linear amplification range. The
change in CT (ΔCT) was determined between each individual miRNA compared to the CT
observed from C666 cells, and the change in ΔCT (ΔΔ CT ) was determined by adjusting
for the difference in a control reaction, which amplifies the U5A small nuclear RNA. The
expression relative to C666 cells was determined as 2Δ Δ CT since each PCR cycle results in
a twofold amplification of each PCR product.
Quantitative RT-PCR for Bim mRNA levels was performed using a Quantitect SYBR green
reverse transcription-PCR kit and has previously described (Kung and Raab-Traub, 2008).
The Primers used were 5’BimELqRT (GCTGTCTCGATCCTCCAGTG) and 3’BimELqRT
(GTTAAACTCGTCTCCAATACG). The ΔCT for Bim was determined in a similar manner
in comparison to the levels in the pcDNA3 control cells and the ΔΔ CT was calculated using
a reaction amplifying GAPDH as a control reaction. The primers used to amplify GAPDH
were qGAPDH5’ (TGCACCACCAACTGCTTAGC) and qGAPDH3’
(GAGGGGCCATCCACAGTCTT). Again, the expression relative to control cells was
determined as 2Δ Δ CT.
Microarray analysis
Total RNA was prepared using the RNeasy Plus Mini Kit (Qiagen) from AGS cells
expressing Cluster I and Cluster II as well as double negative pcDNA3 controls. RNA was
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then amplified and hybridized to a dual color 4×44K whole Human genome microarray
(Agilent) by the UNC Lineberger Comprehensive Cancer Center Genomics and
Bioinformatics Core Facility. Microarrays were scanned using an Axon 4200 Scanner
(Molecular Devices) and normalized using GenePix 5.0 software. Normalized data was
uploaded into the University of North Carolina Microarray Database and is available for
public download at http://genome.unc.edu. Normalized data was also analyzed using
Genespring GX software (Agilent). Genes that showed decreased expression in miRNA
expressing cells compared to controls in all four arrays were considered in further analysis.
Downregulated genes were narrowed down by selecting only those that contained reference
to involvement in apoptosis according the Gene Ontology annotations in Genespring GX. A
table containing the expression data for the 133 genes that met this criterion is contained in
the supplementary materials (Supplementary Table 1). Potential miRNA target sites within
the 3’UTR of these genes were identified using the publicly available PITA software
(Kertesz et al., 2007). ΔΔG scores of −9.00 or lower were considered to be potential
miRNA target sites (Supplementary Table 2).
Luciferase Assays
Stable miRNA expressing AGS cells and controls were grown to 75% confluency in 6 well
plates. The cells were then transfected with 250 ng of reporter with Lipofectamine 2000
(Invitrogen) according the manufacturer’s instructions. After 24 hours the transfection
reagent was removed and replaced with fresh media. At 48 hours after transfection cells
were harvested and assayed using a Dual-Luciferase Reporter Assay System (Promega)
according to manufacturer’s instructions. Luciferase activity values were obtained using an
LMax Luminometer (Molecular Devices). Renilla luciferase activity was first normalized to
the control Firefly luciferase activity and then normalized to the empty reporter construct.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. The structure of the EBV BARTs
The EBV BART miRNAs are expressed from the first two introns of the BART RNAs. In
order to express these miRNAs exogenenously, the DNA sequences spanning the miRNAs
was cloned as two clusters into pcDNA3 expression vectors. Cluster I contains eight
miRNAs from the first intron. Cluster II contains 11 miRNAs from the second intron as well
as miR-BART18 which is just upstream of exon 2. miR-BART2, which is contained in the
intron between exons 4 and 5, and miR-BART21, which is upstream of miR-BART18 were
not included in this study.
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Figure 2. Generation of stable cell lines that express the BART miRNAs
AGS cells were transfected with two pcDNA3 vectors containing Cluster I or Cluster II as
well as appropriate controls to generate four stable cell lines: Cluster I and Cluster II
expressed together, Cluster I and II by themselves each with a control vector, and a double
control vector line. A. Northern blot analysis of total RNA from the four cell lines for a
miRNA representative of each cluster. RNA from the EBV infected NPC cell line, C666-1,
was used as a positive control for expression. B. Quantitative RT-PCR for the miRNAs
listed above each graph. C666-1 RNA was diluted with AGS RNA that lacks BART
miRNAs to 50%, 20%, 10%, and 4% of the total input RNA. For each miRNA the actual
cycle thresholds obtained are plotted against the theoretical cycle thresholds expected for
each dilution. As a control, qRT-PCR was also performed for the small nuclear RNA U5A,
which would not be expected to differ in abundance between the C666-1 and AGS cell lines.
C. Quantitative RT-PCR of the AGS cell lines. RNA from the four stable cell lines was
assayed for the abundance of mature miRNAs using the same qRT-PCR system. Graphed is
the mean relative abundance of each miRNA in each cell line compared to control C666-1
cells for three independent measurements. Error bars represent the standard error of the
mean.
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Figure 3. Treatment of AGS cell with etoposide
The AGS stable cell lines were grown in culture in the presence of 5 or 25 μM etoposide for
24 hours. A. Control and cells expressing both clusters of miRNAs were harvested and
assayed for the induction of apoptosis by assessing the amount of cleaved PARP, a caspase
3 substrate. Protein lysates were run on a SDS-PAGE gel and analyzed for cleaved PARP by
Western blotting. B. Cells from all four cell lines were harvested and assessed for cleaved
PARP as in A (top panel). Lysates from the experiment shown were also run on a separate
gel and probed with an antibody that recognizes both the pro- and mature form of caspase-3
(bottom panel). C. PARP western blot in B was analyzed by densitometry using Image J
software. The percentage of total PARP that is cleaved for each cell line and each treatment
condition is presented.
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Figure 4. Regulation of BH3-only proteins in AGS cells expressing miRNA clusters
A. Western blot analysis of AGS stable cell lines. Protein lysates were analyzed for
expression of BimEL, PUMAα+β, and Bik. In each case, GRP78 was used as a loading
control. B. Immunoblots for BimEL and PUMAα+β were quantitated by densitometry using
Image J software. Expression levels were normalized to GRP78 loading control. Plotted is
the mean of three independent experiments with error bars representing the standard error of
the mean. C. Total RNA was prepared from each of the four stable AGS cell lines and qRT-
PCR for Bim mRNA was performed. The mean expression level relative to the pcDNA3
control cells in three independent experiments is presented graphically. Error bars represent
standard error of the mean.
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Figure 5. Effects mediated through the Bim 3’UTR
A. A diagram of the Bim mRNA drawn to scale. The green box represents the coding region
of the message. Potential miRNA binding sites predicted by PITA are indicated at their
relative positions in the 3’UTR. Fragments of the message cloned into reporter vectors are
indicated below. B. The indicated luciferase reporter vectors were transfected into AGS
stable cells and assayed for luciferase activity after 48 hours. Each value represents the ratio
of Renilla luciferase/control Firefly luciferase normalized to the control vector in each
individual cell line. Plotted is the mean of at least six independent experiments. Error bars
represent standard error of the mean.
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Figure 6. Regulation of Bim in single miRNA expressing cells
A. Expression levels for the AGS stable cell lines expressing individual miRNAs by
quantitative RT-PCR. RNA from each of the stable cell lines listed was assayed for the
abundance of mature miRNAs using qRT-PCR. For cell lines that express multiple
miRNAs, each bar represents expression of a different miRNA, in the order listed on the x
axis of the graph. The relative abundance of each miRNA in each cell line compared to
control C666-1 cells from three independent experiments is graphed. B. Western blot
analysis of AGS cell lines expressing single miRNAs. Protein lysates were probed for
expression of BimEL, PUMAα+β, and GAPDH as a loading control. C. Immunoblots for
BimEL were analyzed by densitometry using Image J software. The relative signals were
normalized to GAPDH loading control. Plotted is the mean of six independent experiments.
Error bars represent standard error of the mean. D. Luciferase reporter vectors were
transfected into AGS stable cells indicated and assayed for luciferase activity after 48 hours.
Each value represents the ratio of Renilla luciferase/control Firefly luciferase normalized to
the control vector in each individual cell line. Plotted is the mean of two independent
experiments. Error bars represent standard error of the mean.
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